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Abstract
Background: Inhaled dry powder mannitol has established in vivo therapeutic efficacy for enhancing mucociliary
function. However, a single dose necessitates multiple inhalations of a sizeable powder mass. Nebulization of
mannitol by vibrating mesh devices has recently been shown in vitro to impart similar dosing in a comparable or
lesser treatment time. Nevertheless, the limited solubility of mannitol restricted fluid concentrations to 150mg/mL.
The present study examines the feasibility of higher solubility polyols that presumably possess similar therapeutic
properties to mannitol but deliverable at higher concentrations to shorten treatment time. A secondary aim is to
compare delivery by two commercially available mesh nebulizers—the Aeroneb Go and PARI eFlow Rapid.
Methods: A series of formulations containing three polyols (mannitol, sorbitol, and xylitol) of increasing con-
centration in 1% w/v sodium chloride were nebulized. Aerosol characteristics and treatment times were de-
termined primarily by laser diffraction.
Results: Results indicate viscosity is the primary determinant of vibrating mesh nebulizer performance. For both
nebulizers, xylitol 334mg/mL exhibits the greatest osmolar output—double that of 150mg/mL mannitol.
Conclusions: A nebulized xylitol solution has potential clinical application for promoting rapid mucociliary
clearance. Both vibrating mesh nebulizers facilitate quick treatment times. Future in vivo studies would compare
the efficacy of nebulized xylitol to commercial hyperosmolar agents and establish any potential polyol-associated
antibacterial activity.
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Introduction
Mucociliary clearance is impaired in respiratorydisease states such as cystic fibrosis (CF), bronchiecta-
sis, and asthma due to dehydration of the airway surface
liquid (ASL).(1–3) Subsequent mucus stasis and airway ob-
struction provokes and exacerbates airway inflammation and
infection.(2) Moreover, the resultant airway obstruction also
restricts access of critical respiratory medications into the
smaller airways.(4)
Mucoactive therapy with hyperosmolar agents such as
nebulized hypertonic saline, and more recently dry powder
mannitol, have proven in vivo efficacy in precluding these
complications by correcting the underlying hydration de-
fect.(5) The attraction of utilizing polyols (or sugar alcohols)
such as mannitol, is primarily attributed to their minimal
airway transepithelial permeability, which theoretically per-
mits a longer duration of therapeutic action and their
pleasant taste encouraging patient adherence.(3,6–8)
However, dry powder mannitol is currently administered
as 40-mg capsules, with a recommended total dose of
400mg, twice a day.(1,9) Further, efficacious delivery is de-
pendent on the patient’s ability to inhale at a satisfactorily
high flow rate,(7) which is not always achievable by the target
patients. This is understandably tedious and time-consum-
ing, requiring multiple actuations, capsule loadings, and
associated inspiratory maneuvres. The authors previously
examined the feasibility of delivering mannitol as a
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nebulized mucoactive agent using vibrating mesh nebulizers
as an alternative.(10) These modern devices deliver therapeutic
agents much quicker and more efficiently than traditional jet
nebulizers.(11–13) As CF patients generally require nebulization
for delivery of various medications, it would further allow
consolidation of therapy via a single mesh nebulizer device as
opposed to a separate dry powder inhaler.
In this previous study(10) it was found that a similar dose
of mannitol could be delivered by nebulization, in a com-
parable or shorter time than required for delivery of the
equivalent dry powder form. The provision being that co-
formulation with an electrolyte such as sodium chloride was
necessary to achieve practical treatment times and realistic
respirable aerosol fraction (defined as the percentage of
aerosol < 5lm). Mannitol alone in aqueous solution suffered
from frequent intermittent nebulization and large median
droplet size. Increasing sodium chloride concentrations
shortened treatment times and supplemented the overall
osmotic effect. Nonetheless, as mannitol is the primary os-
motic agent, it was suggested sodium chloride concentration
be limited to 1% w/v for future formulations to optimally
balance treatment time with taste tolerability. However, the
key issue remained that mannitol had relatively low aqueous
solubility, restricting fluid concentrations in that study to
150mg/mL.
The implementation of higher solubility polyols, such as
sorbitol and xylitol, as hyperosmolar agents is proposed to
overcome this solubility limitation and shorten treatment
time. Solubilized polyols are expected to work in a similar
manner to nebulized hypertonic saline. Compared to dry
powder mannitol, a nebulized mannitol formulation may
increase the volume of the ASL. However, the significance of
this effect would need to be determined in vivo. The pro-
posed polyols presumably have a similar therapeutic ac-
tion to mannitol, but their higher solubility would allow
for delivery of a similar osmotic effect in a substantially re-
duced drug fluid volume. Sorbitol, as a diastereomer of
mannitol, shares the same molecular weight and is expected
to generate similar aerosol characteristics and effect on air-
way function, but able to achieve greater formulation
concentrations.
Xylitol has a slightly higher osmotic value than mannitol
or sorbitol and retains the low transepithelial permeability
important for prolonged therapeutic effect.(7,8,14) By way of
lowering the salt concentration of the ASL, xylitol in vitro has
demonstrated the potential to augment endogenous antimi-
crobial factors present in airway mucus.(8) Sajjan et al.
(2004)(15) went further to suggest this effect may be a direct
result of increased mucociliary clearance. The safety and tol-
erability of jet-nebulized iso-osmotic (50mg/mL) and hyper-
tonic (100 and 150mg/mL) xylitol for CF patients has been
established.(16,17) However, it is noted that jet-nebulization
was lengthy, with delivery of just 1mL of iso-tonic xylitol
requiring 4.2min.(18) An ongoing clinical trial compares the
efficacy of hypertonic xylitol (5mL of 15% w/v, twice daily)
to hypertonic saline (5mL of 7% w/v, twice daily), with the
primary goal of determining the safety of xylitol and any
significant decrease in airway bacterial colonization in CF
subjects.(17) The effect on colonization is proposed to be a
result of the aforementioned decrease in ASL ionic strength.
However, hypertonic xylitol for the sole purpose of en-
hancing mucociliary clearance has not been studied, nor has
the coupling with vibrating mesh technology to substantially
enhance aerosol delivery.
The current study examines the applicability of these high
solubility polyols coformulated with 1% w/v sodium chlo-
ride as mesh nebulized mucoactive hyperosmolar agents,
with a view to deliver a therapeutic dose at significantly
reduced treatment time compared to dry powder mannitol,
mesh nebulized mannitol, and nebulized hypertonic saline.
The aerosolization characteristics of these novel polyol for-
mulations were compared using two commercially available
vibrating mesh nebulizers.
Materials and Methods
Nebulizer
Two commercially available vibrating mesh nebulizers—
an Aeroneb Go kindly provided by Aerogen (Lot
9136100319; Aerogen, Dangan, Galway, Ireland) and a PARI
eFlow Rapid (Serial Number 9V11E08456; PARI GmbH,
Starberg, Germany)—were used for nebulization. The neb-
ulizers were thoroughly cleaned between nebulizations, with
consideration of the manufacturers’ instructions. This in-
volved rinsing with cold tap water, followed by soaking in
hot tap water for 10min, then rinsing with deionized water.
No detergent was used to minimize potential foreign sub-
stance deposition on nebulizer components (e.g., fragrance).
The nebulizers were dried using compressed air then equil-
ibrated to ambient temperature by a deionizing fan (Serial
25724; Ion Systems, Berkeley, CA, USA) before use. Deio-
nizing fan would mitigate any electrostatic charge on the
plastic surfaces of the nebulizer that may affect aerosol per-
formance. For the eFlow Rapid, the mesh was additionally
reverse-nebulized using the provided Easycare cleaning aid
(PARI GmbH, Starberg, Germany) every six nebulizations to
prevent mesh clogging.
The relatively small number of nebulizations performed
combined with adequate cleaning meant mesh clogging was
not expected to severely affect performance of the nebulizers.
Both nebulizers were retested following completion of the
main experiment to ensure consistency of results that indi-
cated minimal mesh clogging.
Nebulizer fluids
Fresh deionized water (MilliQ, Molsheim, France), sodium
chloride (Batch 232931, LabServ, Clayton, Victoria, Aus-
tralia), mannitol (Batch E236A, Roquette Fre`res, Lestrem,
France), sorbitol (Batch 603650; Unilab, Ajax Chemicals,
Auburn, Australia), and xylitol (Batch 744229, Roquette
Fre`res, Lestrem, France) were used as supplied, to prepare
the following fluids (in 1% w/v saline) for nebulization: (1)
Mannitol (75 and 150mg/mL), for comparison with the
previous study by Chan et al. (2011);10 (2) Sorbitol (75, 150,
300, and 400mg/mL); (3) Xylitol at osmotic concentrations
equivalent to those for sorbitol (63, 125, 251, and 334mg/mL,
respectively). The chemical information and osmotic equiv-
alence among the three polyols is presented in Tables 1 and
2, (19–21) respectively. Based on data from a previous publi-
cation,(10) 1% saline was chosen as the vehicle for the polyol
formulations. This concentration was proposed to impart an
appropriate electrolyte concentration for realizing a practical
treatment time without compromizing taste tolerability. All
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solutions were stored at room temperature (20 – 1C) and
used within 48 h of manufacture.
Particle characterization and instrument selection
Laser diffraction is a quick and well-substantiated method
for size characterization of aqueous aerosols.(22–27) Its utility
as a sizing option has further been confirmed for vibrating
mesh-nebulized aerosols.(24,28) The geometric and aerody-
namic diameter obtained from laser diffraction and cascade
impaction (corrected for evaporation), respectively, exhibit a
high level of correlation.(24,27)
Laser diffractometry with the Spraytec (Malvern, Wor-
cestershire, UK) was used to determine aerosol distribution
and total nebulization time. Air extraction through a Sur-
eGard 1420 nebulizer filter (Lot L69470; BIRD Healthcare
Pty Ltd, Melbourne, Australia) was implemented to main-
tain laser obscuration at 20 – 2% and to prevent aerosol re-
entry into the measurement zone. A new respiratory filter
was used for each nebulization. A 10-mm gap was main-
tained between nebulizer mouthpiece and measurement
zone in accordance with standards for particle sizing with
laser diffractometry set by the European Committee for
Standardization.(29)
Multiple scatter and beam steering were accounted for as
follows: detectors 1–6 were excluded from data analysis to
account for beam steering; an algorithm to correct for mul-
tiple scatter embedded in the Malvern software was acti-
vated, although no significant multiple scattering was
expected as light transmission remained above 70% for all
measurements.(30,31) No significant vignetting was observed.
All experiments were conducted within a climate con-
trolled room with temperature maintained at 20 – 1C and
relative humidity at 30 – 1%. The reservoir of the Aeroneb
Go was filled with 2.5mL and the eFlow Rapid with 3.5mL
of the respective nebulizer fluid prior to nebulization—the
higher volume in the eFlow to compensate for an approxi-
mate 1-mL residual volume incorporated in its medication
reservoir design. The filled nebulizer was weighed, then
again postnebulization, to determine gravimetric output and
residual volume. Particle measurement and extraction was
initiated 5 sec prior to nebulization and ceased 10 sec after no
aerosol was detectable (detection limit at 10% obscuration)
and reservoir confirmed to be empty (Aeroneb Go) or the
polyol fluid fell below the level of the vibrating mesh plate
(eFlow Rapid). Treatment time for the nebulizers was de-
fined as the first to the last instance of detectable aerosol on
the Spraytec. All data points excluding the initial and last
5 sec of nebulization were then averaged for each measure-
ment. The prepared nebulizer fluids (except 400mg/mL
sorbitol) were each analyzed in triplicate.
Aerosol performance assessment
by cascade impaction
A series of nebulizations of two promising formulation
candidates (300mg/mL sorbitol and 334mg/mL xylitol, in
1% w/v saline) was performed on the Next Generation Im-
pactor (NGI) using the Aeroneb Go to assess droplet con-
tent uniformity and reconfirm the correlation with laser
diffractometry. The experiments were performed in triplicate
for each formulation.
To limit the evaporation of nebulized aerosol, the nebu-
lizer and NGI were housed in a polycarbonate box with a
controlled temperature (20– 1C) and relative humidity
(> 95%) to minimize aerosol evaporation. The aerosol im-
pactions were performed at a sampling flow rate of 15L
min - 1 to mimic the midpoint of adult tidal breathing used
with nebulizers. The airflow was activated for 1min prior to
attachment of the nebulizer to allow for environmental
equilibration between the NGI and experimental housing. A
rubber adaptor completed a sealed attachment of the nebu-
lizer to the USP throat of the NGI. Impactor plates were not
coated as it is not required for collection of aqueous aerosol
and a hydrophobic layer may cause unintended post-
deposition movement of the aqueous drug.(32,33)
Mass assay
Following aerosol deposition, the nebulizer and NGI
plates were oven dried at 70C to evaporate any aqueous
phase. The solid deposition was then allowed to cool to
ambient temperature. The nebulizer, adaptor, USP (United
States Pharmacopeia) throat and impactor plates were then
separately rinsed with 20, 5, 5, and 10mL of mobile phase
(50mg/L calcium disodium EDTA (Sigma-Aldrich Chemie
B.V., Zwijndrecht, The Netherlands) in deionized water),
respectively. The various rinsing volumes reflect the ex-
pected solute mass for the sample and an appropriate dilu-
tion for chemical analysis detection. Mass assay of these
samples was performed using high performance liquid
chromatography (HPLC).
Methodology for chromatographic separation of sodium
chloride and mannitol was adapted from Chan et al. (2011).10
The Shimadzu HPLC system was comprised of a CBM-20A
controller, LC-20AT pump, SPD-20A RID-10A refractive in-
dex detector, SIL-20A HT Autosampler and column oven
with LCSolution software (all Shimadzu Corporation, Kyoto,
Japan). It was coupled with a dual column configuration,
consisting of a Sugar-Pak 300· 6.5mm (i.d.) column
Table 1. Chemical Information for Mannitol,
Sorbitol, and Xylitol
D-Mannitol D-Sorbitol Xylitol
CAS number 69-65-8 50-70-4 87-99-0
Molecular formula C6H14O6 C6H14O6 C5H12O5
Molecular weight 182.2 182.2 152.2
Water solubtiliy
(20C) (g/100mL)
18 220 160
Octanol–water partition
coefficient (LogP)
- 3.1 - 5.0 - 5.2
Table 2. Osmole Equivalents for the Various
Concentrations of Polyol Fluids
Polyol fluid concentration (mg/mL)
Osmoles (· 10 - 3)
per 2.5mL Mannitol Sorbitol Xylitol
1.03 75 75 63
2.06 150 150 125
4.12 — 300 251
5.49 — 400 334
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maintained at 77– 1C by a column heater, joined to a Re-
solve C-18 column 150· 3.9mm (all Waters, Milford, MA,
USA). A mobile phase consisting of 50mg/mL calcium dis-
odium EDTA in deionized water was pumped through the
system at a flow rate of 0.5mL$min - 1, with a sample injec-
tion volume of 100 lL.
Sodium chloride, sorbitol, or xylitol were separately dis-
solved in deionized water at sequential concentrations to
obtain calibration curves—0.01 to 1% w/v (R2= 1.00) for
sodium chloride; 0.015 to 15mg/mL (R2 = 1.00) for both
sorbitol and xylitol—for result analysis.
Viscosity measurement
The viscosity of the various nebulized fluids was deter-
mined using a Ubbelohde glass capillary viscometer (Size 0B;
Serial 67795) (Poulten Selfe & Lee Ltd, Essex, UK). Utilization
of the viscometer involved drawing the sample fluid up the
capillary of the secondary bulb on the viscometer then re-
leasing the fluid and measuring the time taken for it to reach
a fixed line. The time was then used to calculate the viscosity.
Measurements were performed in triplicate at 20– 1C (room
temperature) and in a cold room at 5 – 1C (refrigerated
temperature).
Statistical analysis
One-way analysis of variance (ANOVA) was used to
identify any statistically significant differences between the
various fluid formulations ( p < 0.05). Significant differences
were further analyzed with Tukey’s post hoc test to identify
the specific formulations involved. A p-value of < 0.05 was
considered statistically significant.
Results
Laser diffraction
The results from laser diffraction are presented in Table 3
(Aeroneb Go) and Table 4 (eFlow Rapid). Sorbitol 400mg/
mL in 1% w/v saline was assessed once only for both neb-
ulizers as the rate of aerosolization dropped far too signifi-
cantly (no detection at all was observed for the eFlow Rapid)
to be considered as a potential candidate for future study.
For the Aeroneb Go, median particle size (5.7–6.9 lm)
mainly decreases with polyol concentration but increases
again at high concentrations (> 300mg/mL for sorbitol and
> 251mg/mL for xylitol). The respirable fraction (40–43%) is
directly related to particle size. However, although these
characteristics were statistically significant ( p-value < 0.05),
they are clinically negligible. In contrast, nebulizations on the
Table 3. Median volumetric particle size (lm)– SD (GSD), treatment time – SD, aerosol mass output (Gravimetric
Difference Between Nebulizer Pre- and Postnebulization Weight) – SD and Respirable Fraction – SD
for the Aernoeb Go Assuming the Initial 2.5-mL Fluid Charge Was Completely Nebulized
Polyol fluid Median particle size (lm) Treatment time (sec) Mass output (g) Respirable fraction (%)
Mannitol 75mg/mL 6.0 – 0.04 (1.9) 225– 1 1.6 – 0.01 41– 1.1
Mannitol 150mg/mL 5.8 – 0.01 (1.9) 245– 1 1.7 – 0.01 42– 0.3
Sorbitol 75mg/mL 5.9 – 0.05 (1.9) 220– 1 1.5 – 0.02 41– 0.4
Sorbitol 150mg/mL 5.8 – 0.00 (1.9) 230– 1 1.6 – 0.01 43– 0.6
Sorbitol 300mg/mL 5.7 – 0.01 (1.8) 310– 3 1.8 – 0.01 43– 0.1
Sorbitol 400mg/mL 6.0 (1.8) 780 2.1 40
Xylitol 62.6mg/mL 5.9 – 0.03 (1.9) 215– 3 1.5 – 0.03 41– 0.2
Xylitol 125.3mg/mL 5.7 – 0.03 (1.9)) 230– 3 1.6 – 0.01 43– 0.3
Xylitol 250.6mg/mL 5.7 – 0.02 (1.9) 250– 2 1.7 – 0.01 43– 0.2
Xylitol 334.1mg/mL 5.9 – 0.02 (1.9) 320– 1 1.8 – 0.01 42– 0.2
SD, standard deviation.
Table 4. Median Volumetric Particle Size (lm) – SD (GSD), Treatment Time – SD, Aerosol Mass Output
(Gravimetric Difference Between Nebulizer Pre- and Postnebulization Weight)– SD and Respirable
Fraction – SD for the eFlow Rapid Assuming the Initial 3.5mL Fluid Charge ( - 1mL Residual Volume)
Was Completely Nebulized
Polyol fluid Median particle size (lm) Treatment time (s) Mass output (g) Respirable fraction (%)
Mannitol 75mg/mL 4.6 – 0.05 (1.6) 104– 1 2.4 – 0.03 56– 0.3
Mannitol 150mg/mL 4.1 – 0.09 (1.9) 130– 1 2.5 – 0.03 64– 1.9
Sorbitol 75mg/mL 4.5 – 0.03 (1.6) 160– 1 2.4 – 0.03 58– 1.2
Sorbitol 150mg/mL 4.1 – 0.09 (1.6) 150– 1 2.5 – 0.06 65– 1.6
Sorbitol 300mg/mL 3.6 – 0.09 (1.4) 230– 3 2.5 – 0.05 77– 2.4
Sorbitol 400mg/mLa — — — —
Xylitol 62.6mg/mL 4.7 – 0.02 (1.7) 155– 3 2.4 – 0.03 53– 2.1
Xylitol 125.3mg/mL 4.2 – 0.07 (1.6) 180– 3 2.4 – 0.04 63– 1.6
Xylitol 250.6mg/mL 3.9 – 0.06 (1.5) 230– 2 2.5 – 0.07 70– 1.1
Xylitol 334.1mg/mL 3.6 – 0.08 (1.4) 280– 1 2.5 – 0.05 80– 1.2
aNo aerosol detected for Sorbitol 400mg/mL.
SD= standard deviation.
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eFlow Rapid imparted considerable changes in particle size
(3.6–4.7lm) and respirable fraction (53–80%) related to
polyol concentrations. For both nebulizers, treatment times
were directly correlated to polyol concentration. Sorbitol at
400mg/mL exhibited a disproportionately high treatment
time compared to concentrations at £ 300mg/mL.
There was also a slight increase in mass output with
polyol concentration for the Aeroneb Go. For this nebulizer,
it is important to note that all charged fluid (2.5mL,
weighing approximately 2.5 g) is nebulized. Loss of mass
measured postaerosolization, represents significant droplet
impaction and deposition at the base of the nebulizer
chamber. Conversely, the eFlow Rapid nebulizes until
reaching an in-built residual volume of approximately 1mL,
and there is minimal loss by deposition within the device.
Figure 1 shows the osmolar output rate of respirable sized
aerosol for various polyol formulations. Comparable output
between polyol formulations at the lower two concentra-
tions (75mg and 150mg/mL mannitol and sorbitol; 63 and
125mg/mL xylitol) was observed. For both nebulizers,
maximum output rate was achieved at a concentration of
300mg/mL for sorbitol and 334mg/mL for xylitol, the latter
formulation approximately doubling the output relative to
150mg/mL mannitol.
Cascade impaction
Comparison of important values between cascade im-
paction and laser diffraction for 300mg/mL sorbitol and
334mg/mL xylitol, in 1% w/v saline is illustrated in Table 5.
The median particle size for the xylitol formulation showed a
clear correlation between the two sizing methods. There was
a statistically significant difference ( p-value < 0.05) between
the methods for the sorbitol fluid but is not considered
clinically significant. The geometric standard deviation and
aerosolized mass also demonstrated slight differences.
Figures 2 and 3 depict the mean aerosol mass distribution
for the two aforementioned formulations recovered by mass
assay. In both cases, no sizeable differences were observed
between the respective proportions of polyol and sodium
chloride.
Fluid viscosity
The viscosity of the various polyol fluids is presented in
Table 6. Viscosity increases with polyol concentration for all
fluids and is inversely related to temperature. At both room
and refrigerated temperatures, sorbitol solutions shares
similar viscosity values with the mannitol formulations. Both
these polyols exhibit slightly higher viscosity at all equiva-
lent osmolar concentrations relative to the xylitol solutions.
Discussion
The physicochemical properties of fluids for nebulization
affect aerosol generation, particularly for vibrating mesh
type nebulizers.(34) Of primary importance is the high elec-
trostatic charge present in aqueous solutions that work to
inhibit the flow and detachment of fluid through the
mesh.(35–37) Introduction of an electrolyte suppresses this
FIG. 1. Respirable aerosol
output and viscosity (at 20C)
for nebulized polyol fluids
(error is not charted as error
bars are too small to be
visible).
Table 5. Comparison of Median Particle Size,
Geometric Standard Deviation, and Aerosol
Mass Between Cascade Impaction and Laser
Diffraction for 300mg/mL Sorbitol,
and 334mg/mL Xylitol, in 1% Saline
Median
particle
size (lm)
Geometric
standard
deviation
Aerosol
mass
output (g)
Sorbitol 300mg/mL
Laser diffraction 5.7 – 0.01 1.8 – 0.00 1.8 – 0.01
Cascade impaction 5.9 – 0.08 2.1 – 0.10 1.75 – 0.00
Xylitol 334.1mg/mL
Laser diffraction 5.9 – 0.02 1.9 – 0.01 1.8 – 0.01
Cascade impaction 5.9 – 0.05 2.2 – 0.01 1.76 – 0.00
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charge, considerably improving particle size and treatment
times.(10,37,38) In the current study, this was accounted for by
the obligatory 1% w/v saline component in the various
polyol formulations.
The key fluid property determining nebulizer perfor-
mance in the current study is thus proposed to be viscosity,
which increases with increasing polyol concentration in
aqueous solutions.(39) Increasing viscosity decreases droplet
size, but is countered by prolonged treatment time as seen
for both nebulizers in Tables 3 and 4. Further, nebulization
slows down or completely halts at a viscosity value depen-
dent on the mesh nebulizer.(38) Indeed, this relationship was
observed for the highest sorbitol concentration. A marked
drop in output (Aeroneb Go) or a nondetectable level of
aersolization (eFlow Rapid) is eventually observed at
400mg/mL (Fig. 1), the fluid viscosity (3.8 – 0.01 cSt) pre-
sumably having exceeded the aforementioned critical value.
For both nebulizers, xylitol output plateaus at the equivalent
of 400mg/mL sorbitol (334mg/mL xylitol) without reaching
the same precipitous decline in output seen for sorbitol. This
similarity in output may be attributed to its lower relative
molecular mass permitting greater osmolar equivalence with
a lower solute mass, and hence, lesser contribution to vis-
cosity (2.7 – 0.01 cSt for 334mg/mL xylitol). Furthermore, the
rate of viscosity increase is slower for the equivalent xylitol
concentrations (Fig. 1). The critical viscosity for the Aero-
neb Go and eFlow Rapid is thus inferred to be at a point
between 2.7 and 3.8 cSt. It is further noted that the solute
concentrations of the sorbitol and xylitol sample fluids were
considerably below their saturation points. Thus, whereas
for mannitol the limiting aspect was aqueous solubility,
viscosity is the ultimate factor determining maximal feasible
fluid concentration for sorbitol and xylitol.
Both xylitol and sorbitol achieved superior osmolar output
compared to solubilized mannitol. These higher outputs
were observed at concentrations beyond the osmolar equiv-
alent of 150mg/mL mannitol, confirming the importance of
high polyol solubility for realizing enhanced dosing cap-
abilities. At 334mg/mL xylitol the osmolar output is double
of that achieved with 150mg/mL mannitol (Fig. 1). How-
ever, both the nebulizers have clear differences in perfor-
mance. The shorter treatment time of the eFlow Rapid may
be explained by its significantly greater number of mesh
holes (four times that of the Aeroneb Go), which directly
FIG. 2. Mass distribution for
sorbitol 300mg/mL in 1%
saline (error bars not shown
as negligible).
FIG. 3. Mass distribution
for xylitol 334mg/mL in 1%
saline (error not shown as
negligible).
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relates to the number of aerosol droplets generated per time
and hence output rate.(40) Further, the smaller droplet sizes
compared to the Aeroneb Go are presumeably due to
smaller mesh hole sizes that also confer significantly greater
susceptibility to viscosity changes (Tables 3 and 4). These
characteristics are observed in the high respirable fractions
for the eFlow Rapid that ranges between 53 and 80%. Dif-
ferences in geometric standard deviation between the vari-
ous formulations are minor and unlikely to be of clinical
significance. Thus, xylitol may be a preferable alternative to
nebulized mannitol that substantially improves the efficiency
of hyperosmolar delivery without appreciably altering
aerosol properties.
The results of cascade impaction for the Aeroneb Go
demonstrate good overall correlation with laser diffraction.
Variation in the geometric standard deviation are expected
due to detector exclusion in laser diffraction measurements
to account for beam steering.(10) More importantly, mass
assay did not show any significant separation between sor-
bitol and sodium chloride (Fig. 2) or xylitol and sodium
chloride (Fig. 3). This suggests the combination of the solutes
did not adversely affect the capability to deliver a uniform
dose of polyol throughout the course of nebulization.
A recurring issue is the visible deposition, and hence loss,
of aerosol within the chamber of the Aeroneb Go as a
consequence of downward aerosol velocity (Table 3). This
loss of aerosol may function analogous to the in-built 1-mL
residual volume of the eFlow Rapid that functions to prevent
patient overdosing by restricting total aerosol delivery
amount to that of a less efficient jet nebulizer. Nonetheless,
the Aeroneb Go was employed as it demonstrates consis-
tent performance in aerosol characteristics and output rate
that are useful for in vitro reproducibility and comparisons.
However, for in vivo studies, the greater aerosol delivery
efficiency of the eFlow Rapid may be preferred.
The present study has established xylitol as having the
greatest potential among the sampled polyols for nebulized
delivery using a mesh device. Increasing electrolyte concen-
tration would decrease treatment times while simultaneously
boosting the osmotic effect of the formulation.(10) It is noted
that increasing ASL salt concentration may suppress en-
dogenous airway immune factors.(8) However, the effect on
respiratory defence is not expected to be problematic, as
safety of hypertonic saline for cystic fibrosis patients is al-
ready well established. In addition, the indication for xylitol
in the current study is to enhance mucociliary clearance,
which in itself is expected to enhance bacterial clearance.
In vivo studies are necessary to titrate sodium chloride
concentrations according to patient taste tolerability.
In vivo studies are further required also to determine
the effective dose for nebulized xylitol, support its effi-
cacy for enhancing mucociliary clearance and compare its
performance to other hyperosmolar agents. The retention
time of jet-nebulized iso-osmotic xylitol in the airway of
healthy human subjects is reported to be only three hours,
which was significantly less than those determined from
in vitro studies.(41) Comparison to the study by the current
authors,(10) is, however, limited for reasons including a no-
tably prolonged mean nebulization time (48min), a signifi-
cantly lower concentration (10mL, 5% w/v) of nebulized
xylitol fluid, and delivery by jet nebulization, which is ex-
pected to have inferior lung delivery compared to vibrating
mesh technology. Moreover, the epithelial integrity and
permeability of respiratory systems in CF patients are likely
different to those of a healthy subject further affecting xylitol
retention times.
Increasing viscosity of polyol aqueous solutions with
polyol concentration was the ultimate limiting factor, caus-
ing an abrupt drop in nebulizer performance beyond a crit-
ical viscosity as demonstrated by sorbitol at 400mg/mL.
Although the formulations are expected to be stable and
unlikely to require refrigeration, colder storage conditions, if
used, would increase viscosity (Table 6), which could po-
tentially limit viability of the higher polyol concentrations. It
is anticipated that the current coformulated electrolyte con-
centration (1% sodium chloride) may be increased in future
studies to shorten treatment times while boosting osmotic
delivery.
Conclusions
The present study clearly demonstrates that utilizing
higher solubility polyols, especially xylitol, is a viable
method of enhancing the rate of therapeutic osmolar delivery
by mesh nebulization. Xylitol exhibited the greatest potential
for clinical application, with 334mg/mL xylitol doubling the
output achieved by near-saturated mannitol solution
(150mg/mL). Administration of polyols in the current study
is primarily aimed at vibrating mesh nebulizers, with both of
the tested devices being able to facilitate rapid delivery
times. However, the higher cost of vibrating mesh nebulizers
could be prohibitive for some patients who may instead
prefer jet nebulization or dry powder mannitol.
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